Tue, Dec 23, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

Swiss FoHFs house Harcourt’s AuM increased to $4.7bn in H1-2010

Monday, August 30, 2010
Opalesque Industry Update - Harcourt Investment Consulting AG, the Switzerland-based global alternative investment solutions provider, announces that assets under management as of 30 June 2010 have reached USD 4.7 billion, corresponding to a growth of USD 200 million for the first half of 2010.

[Harcourt’s AuM were at $3.9bn in the first half of 2009, $4.5bn at the end of 2009.]

The asset increase derives from existing as well as from new clients. The majority of these inflows were originated from institutional clients.

In the first half of 2010, Harcourt successfully launched Vonda UCITS, its first UCITS compliant FoHF. The Fund combines CTA and Macro investments with the benefits of the UCITS Framework, which provides EU-regulated liquidity and diversification guidelines.

Furthermore, the firm launched Belmont Commodity Trading, a commodity FoHF fully dedicated to investing in natural resources fund managers, in partnership with AC Investment Management LLC.

Harcourt’s outlook for the second half of 2010 remains positive.

(Press release)


Harcourt AG is a global leading provider of alternative investment solutions for institutional investors. Founded in 1997, the company has its headquarters in Zurich with offices in New York, Hong Kong, Stockholm, Geneva, Madrid and Cayman Islands. Harcourt is owned by strategic partner Vontobel Group. The company manages USD 4.7bn and employs a staff of 70 professionals. Harcourt is exclusively focused on alternative investments and has an excellent track record of superior risk adjusted returns. www.harcourt.ch


Bg

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for